SpringWorks Therapeutics–JPMorgan Chase: investor conference, 201801 supply service SpringWorks presents at JP Morgan Healthcare Conference 2018

	Period	2018-01-09
	Region	San Francisco, CA
	Country	United States (USA)
	Partner, 1st	SpringWorks Therapeutics Inc. (Nasdaq: SWTX)
	Partner, 2nd	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 36th Annual Healthcare Conference 2018 San Francisco
	Product 2	drug development
	Person	Sullivan, Lara S. (Pyxis Oncology 201912– CEO before SpringWorks Tx + Pfizer + McKinsey + Paul Capital Partners)
	Person 2	Islam, Saqib (SpringWorks Therapeutics 201709– CFO + CBO before Alexion + Moderna Therapeutics)

SpringWorks Therapeutics, Inc.. (1/5/18). "Press Release: SpringWorks Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference". New York, NY.

SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference. Lara S. Sullivan, M.D., President and Founder, and Saqib Islam, Chief Financial Officer and Chief Business Officer, are scheduled to present at 1:30 p.m. PT on Tuesday, January 9, 2018 at the Westin St. Francis in San Francisco, CA.

“Having launched SpringWorks Therapeutics only four months ago, we are honored to have been selected to present at the J.P. Morgan Healthcare Conference,” stated Mr. Islam. “Our collaborative, patient-centric business model is providing innovative ways to advance promising, investigational therapies that may be otherwise trapped on the sidelines in larger pharmaceutical and biotech companies. We look forward to sharing highlights of our novel approach and late-stage pipeline as we enter a catalyst-rich 2018.”

About SpringWorks Therapeutics

SpringWorks Therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities. The company’s collaborative business model is designed to deliver both social and financial returns via partnerships with a variety of stakeholders, including patients, families, foundations, scientists, academia, biopharmaceutical partners, funders and philanthropists. For more information, please visit www.springworkstx.com.

Contacts

W2Opure

Investor Contact:
Courtney Dugan, 212-257-6723
cdugan@w2ogroup.com
or
Media Contact:
Katie Engleman, 910-509-3977
kengleman@w2ogroup.com